JANX Earnings & Financial Statements
Janux Therapeutics, Inc.
$17.13
-$0.05(-0.29%)
57
Overall
60
Value
63
Tech
50
Quality
Market Cap
$1.05B
Volume
614.59K
52W Range
$12.12 - $35.34
Target Price
$30.94
JANX earnings and financial statements: Janux Therapeutics, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
JANX Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $10.00M | $10.59M | $8.08M | $8.61M | $3.64M |
| Operating income | -$157.67M | -$98.85M | -$72.98M | -$67.09M | -$32.93M |
| EBITDA | -$111.60M | -$66.93M | -$56.34M | -$65.97M | -$32.73M |
| Net income | -$113.63M | -$68.99M | -$58.29M | -$63.06M | -$32.67M |
| EPS (diluted) | $-1.83 | $-1.28 | $-1.32 | $-1.52 | $-1.39 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $1.00B | $1.06B | $380.41M | $364.01M | $379.82M |
| Total liabilities | $44.74M | $38.73M | $36.06M | $43.27M | $13.50M |
| Shareholders’ equity | $956.82M | $1.02B | $344.35M | $320.74M | $366.33M |
| Cash and equivalents | $52.33M | $430.61M | $19.20M | $51.43M | $35.58M |
| Long-term debt | $19.75M | $21.28M | $23.02M | $24.54M | - |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$82.23M | -$43.81M | -$50.58M | -$42.92M | -$16.98M |
| Capital expenditure | -$1.04M | -$359.0K | -$1.85M | -$6.45M | -$1.48M |
| Free cash flow | -$83.28M | -$44.17M | -$52.42M | -$49.37M | -$18.46M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | JANX | $17.13 | -0.3% | 614.59K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Janux Therapeutics, Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW